Aspire Biopharma (NASDAQ:ASBP) Stock Price Up 1.4% – Here’s Why

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP)’s stock price rose 1.4% during trading on Tuesday . The company traded as high as $1.5918 and last traded at $1.47. Approximately 221,040 shares were traded during trading, a decline of 69% from the average daily volume of 706,348 shares. The stock had previously closed at $1.45.

Wall Street Analyst Weigh In

ASBP has been the subject of several research analyst reports. Wall Street Zen upgraded Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Aspire Biopharma Stock Performance

The company has a market cap of $3.52 million, a PE ratio of -0.07 and a beta of 0.88. The company has a fifty day moving average of $2.38 and a two-hundred day moving average of $8.66.

Institutional Investors Weigh In On Aspire Biopharma

Large investors have recently added to or reduced their stakes in the stock. Optivise Advisory Services LLC grew its position in shares of Aspire Biopharma by 120.9% during the 2nd quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after buying an additional 128,660 shares in the last quarter. Jane Street Group LLC raised its position in shares of Aspire Biopharma by 625.8% in the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares in the last quarter. CIBC Bancorp USA Inc. bought a new stake in Aspire Biopharma during the third quarter valued at about $28,000. Finally, XTX Topco Ltd raised its holdings in Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after purchasing an additional 237,620 shares in the last quarter. 19.17% of the stock is owned by hedge funds and other institutional investors.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.